

## **RAW SEQUENCE LISTING**

**The Biotechnology Systems Branch of the Scientific and Technical  
Information Center (STIC) no errors detected.**

Application Serial Number: 09/647,457 E  
Source: IFW16  
Date Processed by STIC: 06/30/2005

# ***ENTERED***



IFW16

## RAW SEQUENCE LISTING

DATE: 06/30/2005

PATENT APPLICATION: US/09/647,457E

TIME: 09:01:26

Input Set : A:\09-647457 seq 6-24-05.ST25.txt

Output Set: N:\CRF4\06302005\I647457E.raw

3 <110> APPLICANT: Yeda Research and Development Company Ltd.  
 5 <120> TITLE OF INVENTION: ASSAY FOR THE DIAGNOSIS OF SCHIZOPHRENIA BASED ON A NEW  
 PEPTIDE  
 7 <130> FILE REFERENCE: 24390 (1276302)  
 9 <140> CURRENT APPLICATION NUMBER: 09/647,457E  
 C--> 10 <141> CURRENT FILING DATE: 2000-11-29  
 12 <150> PRIOR APPLICATION NUMBER: PCT/IL99/00190  
 13 <151> PRIOR FILING DATE: 1999-09-29  
 15 <150> PRIOR APPLICATION NUMBER: 123925  
 16 <151> PRIOR FILING DATE: 1998-04-02  
 18 <160> NUMBER OF SEQ ID NOS: 15  
 20 <170> SOFTWARE: PatentIn version 3.2  
 22 <210> SEQ ID NO: 1  
 23 <211> LENGTH: 17  
 24 <212> TYPE: PRT  
 25 <213> ORGANISM: Unknown  
 27 <220> FEATURE:  
 28 <223> OTHER INFORMATION: being the immunologically active epitope  
 31 <220> FEATURE:  
 32 <221> NAME/KEY: MISC\_FEATURE  
 33 <222> LOCATION: (1)..(16)  
 34 <223> OTHER INFORMATION: Xaa(8) is C, G, or P; Xaa(17) is R or absent; provided that  
 35 when Xaa(8) is C, then Xaa(17) is absent, and when Xaa(8) is  
 36 either G or P, then Xaa(17) is R.  
 38 <400> SEQUENCE: 1  
 W--> 40 Leu Val Val Gly Leu Cys Thr Xaa Gln Ile Lys Thr Gly Pro Ala Cys  
 41 1 5 10 15  
 44 Xaa  
 47 <210> SEQ ID NO: 2  
 48 <211> LENGTH: 28  
 49 <212> TYPE: PRT  
 50 <213> ORGANISM: Unknown  
 52 <220> FEATURE:  
 53 <223> OTHER INFORMATION: being the immunologically active epitope  
 55 <400> SEQUENCE: 2  
 57 Ser Gly Glu Thr Glu Asp Thr Phe Ile Ala Asp Leu Val Val Gly Leu  
 58 1 5 10 15  
 61 Cys Thr Gly Gln Ile Lys Thr Gly Ala Pro Cys Arg  
 62 20 25  
 65 <210> SEQ ID NO: 3  
 66 <211> LENGTH: 16  
 67 <212> TYPE: PRT  
 68 <213> ORGANISM: Unknown  
 70 <220> FEATURE:

## RAW SEQUENCE LISTING

DATE: 06/30/2005

PATENT APPLICATION: US/09/647,457E

TIME: 09:01:26

Input Set : A:\09-647457 seq 6-24-05.ST25.txt

Output Set: N:\CRF4\06302005\I647457E.raw

71 <223> OTHER INFORMATION: peptide capable of binding antibodies that are found in elevated levels in body fluids of schizophrenic patients.

72 levels in body fluids of schizophrenic patients.

74 <400> SEQUENCE: 3

76 Leu Val Val Gly Leu Cys Thr Cys Gln Ile Lys Thr Gly Pro Ala Cys

77 1 5 10 15

80 <210> SEQ ID NO: 4

81 <211> LENGTH: 20

82 <212> TYPE: PRT

83 <213> ORGANISM: Unknown

85 <220> FEATURE:

86 <223> OTHER INFORMATION: peptide capable of binding antibodies that are found in elevated levels in body fluids of schizophrenic patients.

87 levels in body fluids of schizophrenic patients.

89 <400> SEQUENCE: 4

91 Ile Ala Asp Leu Val Val Gly Leu Cys Thr Gly Gln Ile Lys Thr Gly

92 1 5 10 15

95 Ala Pro Cys Arg

96 20

99 <210> SEQ ID NO: 5

100 <211> LENGTH: 19

101 <212> TYPE: PRT

102 <213> ORGANISM: Unknown

104 <220> FEATURE:

105 <223> OTHER INFORMATION: peptide capable of binding antibodies that are found in elevated levels in body fluids of schizophrenic patients

106 levels in body fluids of schizophrenic patients

108 <400> SEQUENCE: 5

110 Ala Asp Leu Val Val Gly Leu Cys Thr Gly Gln Ile Lys Thr Gly Ala

111 1 5 10 15

114 Pro Cys Arg

118 <210> SEQ ID NO: 6

119 <211> LENGTH: 18

120 <212> TYPE: PRT

121 <213> ORGANISM: Unknown

123 <220> FEATURE:

124 <223> OTHER INFORMATION: peptide capable of binding antibodies that are found in elevated levels in body fluids of schizophrenic patients

125 levels in body fluids of schizophrenic patients

127 <400> SEQUENCE: 6

129 Asp Leu Val Val Gly Leu Cys Thr Gly Gln Ile Lys Thr Gly Ala Pro

130 1 5 10 15

133 Cys Arg

137 <210> SEQ ID NO: 7

138 <211> LENGTH: 17

139 <212> TYPE: PRT

140 <213> ORGANISM: Unknown

142 <220> FEATURE:

143 <223> OTHER INFORMATION: peptide capable of binding antibodies that are found in elevated levels in body fluids of schizophrenic patients

144 levels in body fluids of schizophrenic patients

146 <400> SEQUENCE: 7

148 Leu Val Val Gly Leu Cys Thr Gly Gln Ile Lys Thr Gly Ala Pro Cys

149 1

5

10

15

## RAW SEQUENCE LISTING

DATE: 06/30/2005

PATENT APPLICATION: US/09/647,457E

TIME: 09:01:26

Input Set : A:\09-647457 seq 6-24-05.ST25.txt

Output Set: N:\CRF4\06302005\I647457E.raw

```

152 Arg
156 <210> SEQ ID NO: 8
157 <211> LENGTH: 17
158 <212> TYPE: PRT
159 <213> ORGANISM: Unknown
161 <220> FEATURE:
162 <223> OTHER INFORMATION: peptide capable of binding antibodies that are found in
elevated
163         levels in body fluids of schizophrenic patients
165 <400> SEQUENCE: 8
167 Leu Val Val Gly Leu Cys Thr Gly Gln Ile Lys Thr Gly Pro Ala Cys
168 1             5             10             15
171 Arg
175 <210> SEQ ID NO: 9
176 <211> LENGTH: 17
177 <212> TYPE: PRT
178 <213> ORGANISM: Unknown
180 <220> FEATURE:
181 <223> OTHER INFORMATION: peptide capable of binding antibodies that are found in
elevated
182         levels in body fluids of schizophrenic patients
184 <400> SEQUENCE: 9
186 Leu Val Val Gly Leu Cys Thr Pro Gln Ile Lys Thr Gly Pro Ala Cys
187 1             5             10             15
190 Arg
194 <210> SEQ ID NO: 10
195 <211> LENGTH: 20
196 <212> TYPE: PRT
197 <213> ORGANISM: Unknown
199 <220> FEATURE:
200 <223> OTHER INFORMATION: peptide capable of binding antibodies that are found in
elevated
201         levels in body fluids of schizophrenic patients
203 <400> SEQUENCE: 10
205 Ser Gly Glu Thr Glu Asp Thr Phe Ile Ala Asp Leu Val Val Gly Leu
206 1             5             10             15
209 Cys Thr Gly Gln
210         20
213 <210> SEQ ID NO: 11
214 <211> LENGTH: 16
215 <212> TYPE: PRT
216 <213> ORGANISM: Unknown
218 <220> FEATURE:
219 <223> OTHER INFORMATION: peptide capable of binding antibodies that are found in
elevated
220         levels in body fluids of schizophrenic patients
222 <400> SEQUENCE: 11
224 Val Val Gly Leu Cys Thr Gly Gln Ile Lys Thr Gly Ala Pro Cys Arg
225 1             5             10             15
228 <210> SEQ ID NO: 12
229 <211> LENGTH: 12
230 <212> TYPE: PRT
231 <213> ORGANISM: Unknown

```

## RAW SEQUENCE LISTING

DATE: 06/30/2005

PATENT APPLICATION: US/09/647,457E

TIME: 09:01:26

Input Set : A:\09-647457 seq 6-24-05.ST25.txt

Output Set: N:\CRF4\06302005\I647457E.raw

```

233 <220> FEATURE:
234 <223> OTHER INFORMATION: peptide capable of binding antibodies that are found in
elevated
235     levels in body fluids of schizophrenic patients
237 <400> SEQUENCE: 12
239 Cys Thr Gly Gln Ile Lys Thr Gly Ala Pro Cys Arg
240 1           5           10
243 <210> SEQ ID NO: 13
244 <211> LENGTH: 16
245 <212> TYPE: PRT
246 <213> ORGANISM: Unknown
248 <220> FEATURE:
249 <223> OTHER INFORMATION: peptide capable of binding antibodies that are found in
elevated
250     levels in body fluids of schizophrenic patients
252 <400> SEQUENCE: 13
254 Leu Val Val Gly Leu Cys Thr Gly Gln Ile Lys Thr Gly Ala Pro Cys
255 1           5           10           15
258 <210> SEQ ID NO: 14
259 <211> LENGTH: 15
260 <212> TYPE: PRT
261 <213> ORGANISM: Unknown
263 <220> FEATURE:
264 <223> OTHER INFORMATION: peptide capable of binding antibodies that are found in
elevated
265     levels in body fluids of schizophrenic patients
267 <400> SEQUENCE: 14
269 Leu Val Val Gly Leu Cys Thr Gly Gln Ile Lys Thr Gly Ala Pro
270 1           5           10           15
273 <210> SEQ ID NO: 15
274 <211> LENGTH: 16
275 <212> TYPE: PRT
276 <213> ORGANISM: Unknown
278 <220> FEATURE:
279 <223> OTHER INFORMATION: peptide capable of binding antibodies that are found in
elevated
280     levels in body fluids of schizophrenic patients
282 <400> SEQUENCE: 15
284 Leu Val Val Gly Leu Cys Thr Gly Gln Ile Lys Thr Gly Pro Ala Cys
285 1           5           10           15

```

RAW SEQUENCE LISTING ERROR SUMMARY      DATE: 06/30/2005  
PATENT APPLICATION: US/09/647,457E      TIME: 09:01:27

Input Set : A:\09-647457 seq 6-24-05.ST25.txt  
Output Set: N:\CRF4\06302005\I647457E.raw

Please Note:

Use of n and/or Xaa have been detected in the Sequence Listing. Please review the Sequence Listing to ensure that a corresponding explanation is presented in the <220> to <223> fields of each sequence which presents at least one n or Xaa.

Seq#:1; Xaa Pos. 8,17

**VERIFICATION SUMMARY**

DATE: 06/30/2005

PATENT APPLICATION: US/09/647,457E

TIME: 09:01:27

Input Set : A:\09-647457 seq 6-24-05.ST25.txt

Output Set: N:\CRF4\06302005\I647457E.raw

L:10 M:271 C: Current Filing Date differs, Replaced Current Filing Date

L:40 M:341 W: (46) "n" or "Xaa" used, for SEQ ID#:1 after pos.:0

M:341 Repeated in SeqNo=1